Gilead tags Merck for first-line triple negative breast cancer trial
pharmaphorum
OCTOBER 29, 2021
Gilead’s Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan) will be paired with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in a new phase 3 trial in previously-untreated subjects with locally advanced or metastatic TNBC. While its headline revenue of $7.4
52 
Let's personalize your content